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Background: Alzheimer’s disease (AD) is the most common cause of dementia among the elderly. To clarify
pathogenesis of AD, thousands of reports have been accumulating. However, knowledge of signaling pathways in
the field of AD has not been compiled as a database before.
Description: Here, we have constructed a publicly available pathway map called “AlzPathway” that
comprehensively catalogs signaling pathways in the field of AD. We have collected and manually curated over 100
review articles related to AD, and have built an AD pathway map using CellDesigner. AlzPathway is currently
composed of 1347 molecules and 1070 reactions in neuron, brain blood barrier, presynaptic, postsynaptic, astrocyte,
and microglial cells and their cellular localizations. AlzPathway is available as both the SBML (Systems Biology
Markup Language) map for CellDesigner and the high resolution image map. AlzPathway is also available as a web
service (online map) based on Payao system, a community-based, collaborative web service platform for pathway
model curation, enabling continuous updates by AD researchers.
Conclusions: AlzPathway is the first comprehensive map of intra, inter and extra cellular AD signaling pathways
which can enable mechanistic deciphering of AD pathogenesis. The AlzPathway map is accessible at http://
alzpathway.org/.Background
Alzheimer’s disease (AD) is the most common cause of
dementia among the elderly. With the advent of the
aging society, 24.3 million people are estimated to suffer
dementia worldwide, increasing to 42.3 million people
by 2020 and 81.1 million by 2040 [1,2]. The total esti-
mated worldwide costs of dementia are US$604 billion
in 2010, and are estimated to increase by 85% to 2030
[3]. The cost for caring for the increasing number of
people with dementia will rise dramatically and thus will
be disastrous burden to our societies within upcoming
10–20 years. To address this social issue, clarification of
the pathogenic mechanism of AD and development of
AD drugs are urgently expected.
Genetic association with putative AD susceptibility
genes has been studied and collected as a publicly* Correspondence: ogishima@sysbioevo.org
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reproduction in any medium, provided the oravailable database called AlzGene (http://www.alzgene.
org/) [4]. Pathological signaling has been also studied
and two core pathological hallmarks of AD, amyloid pla-
ques and neurofibrillary tangles (NFT) accumulation,
have been elucidated intensively. However, wealth of this
information has become increasingly difficult to follow,
much less interpret, and has not been integrated before.
Integration of pathway knowledge bridging amyloid pla-
ques and neurofibrillary tangles has been still missing.
Efforts to construct an AD pathway map have been
made before, however, these maps are overviews or partial
maps of an AD pathway, and are not comprehensive
maps. Manual elaboration is still required to construct a
comprehensive and accurate map of a particular signaling
pathway [5]. Efforts to manually construct pathway maps
of particular signaling, e.g., Toll-like receptor, EGFR, RB/
E2F, mTOR signalings, and dendritic cell signaling in re-
sponse to pathogenes, have been made before [6-10].
In this study, we collected and manually curated over
100 review articles involving in AD, and built an AD
pathway map using CellDesigner [11], a modeling editorLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1752-0509/6/52for biochemical pathways. AlzPathway is the first com-
prehensive map of intra, inter and extra cellular signal-
ing pathways of particular disease. AlzPathway now
contains 34 canonical pathways such as APP, mitochon-
drial and apoptosis pathways, which are composed of
1347 species (proteins, complexes, simple moecules,
genes, RNAs, ions, degraded products, and phenotypes),
1070 reactions, 129 phenotypes in neuron, brain blood
barrier, presynaptic, postsynaptic, astrocyte, and micro-
glial cells and their cellular localizations. Our AlzPath-
way provides a powerful AD pathway map for
deciphering pathogenesis of AD, and it serves as a path-
way reference database just as AlzGene for risk-gene
reference database. AlzPathway allows us to not onlyFigure 1 Overview of AlzPathway overlaid with canonical pathway an
molecules, 1070 reactions, and 129 phenotypes. Original and high resolutio
the SBML (Systems Biology Markup Language) map for CellDesigner and th
annotation. AlzPathway is also available as the web service (online map) imevaluate candidate risk genes listed by GWAS studies,
but also analyze omics data including DNA microarray
data and RNA-seq data to reveal pathogenesis of AD.
Our pathway map will be an indispensable basic re-
source for both clarification of the pathogenic mech-
anism of AD and development of AD drug to address
social issues caused by AD.
Construction and content
Construction of AlzPathway
We collected 123 review articles related to AD accessible
from PubMed. We then manually curated these review arti-
cles, and have built an AD pathway map by using CellDe-
signer. In PubMed, the number of research articlesnotations for explanation of map. AlzPathway consists of 1347
n version of AlzPathway is available at http://alzpathway.org/ as both
e high resolution image map without overlay of canonical pathway
plemented by using Payao system.
Figure 2 (See legend on next page.)
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Figure 2 Detailed view of AlzPathway. (a) oligomeric amyloid β formation, (b) MAPT phosphorylation. Notations are based on SBGN
(Systems Biology Graphical Notation). References to the reactions are represented in PubMed ID (PMID) using the MIRIAM scheme.
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cannot collect and manually curate over 80,000 research
articles. To construct AlzPathway, we need to choose arti-
cles among over 80,000 research articles. Review articles
are attempts to chose important articles and summarize
current state of understanding on signaling pathways
involved in Alzheimer’s disease. Therefore, we chose to use
review articles for the curation. Notations are based on the
PD (Process Description) of SBGN (Systems Biology
Graphical Notation) [12] and the map is available in stan-
dardized SBML (Systems Biology Markup Language) [13]
format for file exchange between different tools. Molecules
are distinguished by the following types: proteins, com-
plexes, simple molecules, genes, RNAs, ions, degraded pro-
ducts, and phenotypes. Gene symbols are pursuant to the
HGNC symbols. Reactions are also distinguished by the fol-
lowing categories: state transition, transcription, translation,
heterodimer association, dissociation, transport, unknown
transition, and omitted transition. All the reactions have
evidences to the references in PubMed ID using the MIR-
IAM scheme [14]. All the references used for constructing
the AlzPathway are listed in the ‘References for AlzPath-
way’. Cellular types are distinguished by the followings:
neuron, astrocyte, and microglial cells. Cellular compart-
ments are also distinguished by the followings: brain blood
barrier, presynaptic, postsynaptic, and their inner cellular
localizations. AlzPathway is available as both the SBML
map for CellDesigner (Additional file 1; see the section of
Additional files) and the high resolution image map
(Additional file 2; see the section of Additional files).
Imprementation of web service of AlzPathway
AlzPathway is also available as the web service (online
map) implemented by using Payao [15], a community-
based, collaborative web service platform for gene-
regulatory and biochemical pathway model curation, enab-
ling continuous updates by AD researchers. Payao web ser-
vice (online map) is accessible from http://alzpathway.org/.
Instruction on how to access the AlzPathway web service
(online map) is described in the Additional documentation
file (Additional file 3; see the section of Additional files).
Using the Payao system would enable AD researchers not
only to browse reactions and their references in PubMed
ID but also to comment, correct and update AlzPathway in
a community-wide collaboration.
Overview of alzheimer’s disease pathway
Here, we present a map of Alzheimer’s disease signaling
networks (Figure 1). We manually constructed a map ofAlzheimer’s disease signaling networks by assembling mo-
lecular interactions based on published papers using the
modeling software, CellDesigner ver. 4.2 (http://cellde-
signer.org/).
The AlzPathway map consists of 1347 species, 1070
reactions, and 129 phenotypes. The molecues shown on
the AlzPathway can be categorized as follows: 650 pro-
teins, 232 complexes, 223 simple molecules, 32 genes,
36 RNAs, 24 ions, and 21 degraded products. The break-
down of reactions is as follows: 401 state transitions, 22
transcriptions, 30 translations, 172 heterodimer associa-
tions, 49 dissociations, 87 transports, 20 unknown tran-
sitions, and 228 omitted transitions. All the 123
references used for constructing the map are listed in
the ‘References for AlzPathway’ [16-138]. The CellDe-
signer software allows the user to access references that
are used as evidences for individual reaction using
PubMed ID (Figure 2).
The map consists of the AD hallmark pathways and
canonical pathways. The AD hallmark pathways are
amyloid β cleavage, amyloid β degradation, APOE-
cholesterol pathway and NFT accumulation, which are
major pathological pathways of AD. On the other hand,
the canonical pathways are acetylcholine production,
cholesterol synthesis, Wnt signaling pathway, Notch sig-
naling pathway, Ubiquitin mediated proteolysis, apop-
tosis, calcium signaling pathway, ER stress, MAPK
signaling pathway, abnormal ceramide accumulation,
ceramide synthesis, reactive oxidation process, regula-
tion of Autophagy, neurotrophin signaling pathway, cell
cycle, arachidonic acid cascade, mTOR signaling path-
way, lipid pathway, lipid raft, inflammation pathway, in-
sulin pathway, and CREB pathway.
AlzPathway is the first comprehensive map of intra,
inter and extra cellular signaling pathways of particular
disease manually constructed. Manual reconstructions of
comprehensive map have been reported before: epider-
mal growth factor receptor signaling, toll-like receptor
signaling network, RB/E2F signaling pathway and mTOR
signaling pathways [6-9], which are molecular signaling
pathways and are not comprehensive intra, inter and
extra cellular signaling pathways of particular disease.
That is, AlzPathway comprehensively catalogs not only
intra but also inter and extracellular signaling pathways
among neuron, glial cell, microglia, presynaptic cell, postsy-
naptic cell, astrocyte, and blood–brain barrier. The brain
and spinal cord are made up of various regions and cells,
including neurons and glial cells. To reveal pathogenic
mechanism of AD, complicated signaling pathways among
Figure 3 (See legend on next page.)
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Figure 3 Binary-relation notation and key molecules of AlzPathway. (a) overview of AlzPathway in binary-relation notation, (b) top 50 high
centrality relations as highlighted primary pathway of AlzPathway.
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cell, astrocyte, and blood–brain barrier should be clarified.
Binary-relation notation and key molecules
As for intuitively understandable notation of AlzPath-
way, we also constructed AlzPathway not only in SBGN
(Systems Biology Graphical Notation) PD (Process De-
scription) notation but also in binary-relation notation
(Figure 3(a)). In SBGN PD notation, a reaction consists
of reactants, modifiers, and products. We converted this
notation to binary-relation notation by decomposing
reactions into those between (1) reactants and products,
and (2) modifiers and products. Molecules are limited to
proteins, complexes, genes, RNAs and phenotype for
simplification. SBGN PD notation is precise notation for
describing pathways, on the other hand the binary-
relation based conventional notation used by molecular
biologists in the current literature, is intuitively under-
standable. To clarifying basic structure of AlzPathway,
we constructed AlzPathway in binary-relation notation,
and found that amyloid β accumulation and hyperpho-
sphorylated tau accumulation are central pathogenesis
signaling pathways in AlzPathway. Binary-relation nota-
tion is provided as a SIF (simple interaction format) file
(Additional file 4) which can be opened by using Cytos-
cape [139].
According to edge betweenness centrality of each reac-
tion, high centrality relations were highlighted as pri-
mary relations. Top 50 high centrality relations are
shown in Figure 3(b). Highlighted binary relations were
so-called AD hallmark pathways: amyloid plagues (amyl-
oid β accumulation) and NFT accumulation (hyperpho-
sphorylated tau accumulation). The γ-secretase produces
amyloid β 1–40, which leads to oligomeric amyloid β
(amyloid β accumulation). Amyloid β 1–42 is related to
cell death, which is amyloid plagues (amyloid β accumu-
lation) and NFT accumulation crucial for AD progres-
sion. On the other hand, APC-AXIN-GSK3B-CTNNB1
complex phosphorylates MAPT and mutant PSEN pro-
motes phosphorylation of MAPT, which lead to MAPT
hyperphosphorylation and NFT accumulation.
Utility and discussion
Access to AlzPathway map
The AlzPathway map is accessible at http://alzpathway.
org/. As described above, AlzPathway is provided as (1)
the SBML map for CellDesigner (Additional file 1), (2)
the web service (online map) implemented by using
Payao accessible from http://alzpathway.org/ (see theAdditional file 3 for instruction on how to access the
AlzPathway online map by Payao), (3) the high reso-
lution image map (Additional file 2), (4) the binary-
relation notation (Additional file 4), (5) the pure SBML
map (Additional file 5) for compatibility with other
SMBL supporting tools, and (6) the BioPAX file for
exchanges of pathway data (Additional file 6). For Nota-
tions are based on the PD (Process Description) of
SBGN (Systems Biology Graphical Notation). The Cell-
Designer software and Payao system allow the user to
access references that are used as evidences for individ-
ual reaction in PubMed ID using the MIRIAM scheme.
They also allow the user to access external resources in-
cluding UniProt and PubChem for individual species
using the MIRIAM scheme. AlzGene information is pro-
vided for individual species using Notes. Expanded ver-
sion of AlzPathway map having external links to Gene
Ontology is also provided (Additional file 7). As for
usage of CellDesigner software, see the documentations
provided at CellDesigner web site. As for usage of Payao
system, see the user’s guide provided at Payao web site.
Community driven update of AlzPathway using payao
We constructed AlzPathway to be comprehensive but not
necessarily to be complete. While continuous curation of
molecular pathways remain a major challenge, the availabil-
ity of Alzpathway through Payao (http://alzpathway.org/)
would enable AD researchers to review, comment and pro-
vide feedbacks to the pathway through the web-based inter-
face (Figure 4). Correction and update of AlzPathway can
be made through comments and feedback from AD
researchers in specific molecules and interactions. By using
Payao system, we envision to reach out to the AD commu-
nity and continuously correct and update AlzPathway. In
addition to community-driven correction and update using
Payao system, we will keep updating our pathway map by
ourselves.
AlzPathway as basic resource for AD study
AlzPathway is comprehensive AD pathway map, and is
expected to be a guidance map in the study of AD. Just as
AlzGene for risk-gene reference database, AlzPathway
serves as a pathway “reference” integrating wealth of path-
way information published before. AlzPathway also serves
for analysis on omics data including DNA microarray data
and RNA-seq data. Availability of AD pathway map in stan-
dardized formats (SBML and SBGN) renders the network
applicable to systems-biology analyses based on various
SBML compliant tools. Therefore, our AD pathway map
Figure 4 AlzPathway on Payao system. Payao system provide community-based, collaborative web service (online map) platform for
pathway manual curation.
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of the pathogenic mechanism of AD and development of
AD drug.
Conclusions
We constructed a publicly available database called “Alz-
Pathway” that comprehensively catalogs signaling pathways
in the field of AD. We have collected and manually curated
over 100 review articles involving in AD, and have built an
AD pathway map using CellDesigner. AlzPathway is the
first comprehensive map of intra, inter and extra cellular
signaling pathways of particular disease for deciphering
pathogenesis of AD. AlzPathway is currently composed of
1347 molecules, 1070 reactions, and 129 phenotypes in
neuron, brain blood barrier, presynaptic, postsynaptic,
astrocyte, and microglial cells and their cellular localiza-
tions. AlzPathway is available as both the SBML (Systems
Biology Markup Language) map for CellDesigner and the
high resolution image map. AlzPathway is also available as
the web service (online map) implemented on Payao, a
community-based, collaborative web service platform for
pathway model curation. The molecular level mechanistic
interactions captured in AlzPathway, together with a
community-driven, web based curation platform, would
provide a comprehensive resource to the AD community
towards deeper insights into AD pathogenesis and identifi-
cation of novel therapeutic targets.Availability and requirements
The AlzPathway map is accessible at http://alzpathway.org/.
The Payao system does not work on a 64 bit mode Linux.
Additional files
Additional file 1: SBML map file of AlzPathway. The SBML map file
alzpathway_sbml_map.xml can be browsed using CellDesigner. Please
download CellDesigner at http://www.celldesigner.org/, install it, and
open the SBML map file alzpathway_sbml_map.xml to browse
AlzPathway map by CellDesigner. As for usage of CellDesigner software,
see the documentations provided at CellDesigner web site: http://www.
celldesigner.org/documents.html.
Additional file 2: High resolution image map of AlzPathway. The
PNG file alzpathway_image_map.png contains a high resolution map
of AlzPathway. This image map does not contain the reference
information used for constructing the AlzPathway. SBML
(CellDesigner) map and Online map (Payao) are recommended to
browse the AlzPathway map.
Additional file 3: Instruction on usage of Payao. The PDF file
alzpathway_payao_access_instruction.pdf contains insturction on usage
of Payao web service (online map). Payao system requires login.
AlzPathway demo user account is prepared for demo use: demo
username is “ap_demo” and the corresponding password is
“4patients”. As for usage of Payao system, see the user’s guide
provided at Payao web site: http://payao.oist.jp:8080/payaologue/doc/
PAYAO_Users_GuideE11.pdf.
Additional file 4: Binary-relation notation file of AlzPathway. The SIF
(simple interaction format) file alzpathway_binary_relation.sif is the binary-
relation notation of AlzPathway map which can be opened by using
Cytoscape.
Additional file 5: Pure SBML map file of AlzPathway. The pure SBML file
Mizuno et al. BMC Systems Biology 2012, 6:52 Page 8 of 10
http://www.biomedcentral.com/1752-0509/6/52alzpathway_pure_sbml.xml is for compatibility with other SMBL
supporting tools.
Additional file 6: BioPAX file of AlzPathway. The BioPAX file
alzpathway_biopax.owl is for exchanges of pathway data.
Additional file 7: Expanded SBML map file of AlzPathway with Gene
Ontology. The SBML map file alzpathway_sbml_map_go.xml is the
expanded version of AlzPathway map (alzpathway_sbml_map.xml) having
external links to Gene Ontology. The SBML map file with the external links
to Gene Ontology requires time to be opened by CellDesigner 4.2, and thus
was provided separately as an expanded SBML map.
Abbreviations
AD: Alzheimer’s disease; SBML: Systems biology markup language;
NFT: Neurofibrillary tangles; PD: Process description; SBGN: Systems biology
graphical notation.
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